MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents ...

The MVA-BN vaccine, designed for smallpox, has shown 58% effectiveness against mpox after a single dose in a Canadian study.

Amid the rising global outbreak of Mpox, two separate studies have shown that the efficacy of Bavarian Nordic’s vaccine ...

Gavi (the Global Alliance for Vaccines and Immunization) has entered an advance purchase agreement with Bavarian Nordic to ...

(RTTNews) - Bavarian Nordic A/S (BAVA) Thursday said that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II ...

First mpox vaccine to obtain prequalification by the WHOApproval will help accelerate access to the vaccine for all African countries COPENHAGEN, Denmark, September 13, 2024 - Bavarian Nordic ...

Bavarian Nordic receives WHO prequalification for IMVANEX as the first vaccine against mpox, accelerating access in African ...

About Bavarian Nordic Bavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, ...

A recent study from Ontario, Canada, has revealed that Bavarian Nordic A/S's smallpox vaccine, marketed as Imvamune in Canada and ...

Bavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, supplied to ...

EU drug regulator approves use of Bavarian Nordic's mpox vaccine, Imvanex for adolescents: Copengagen, Denmark Saturday, September 21, 2024, 10:00 Hrs [IST] Bavarian Nordic A/S, a ...